Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer

Cell Death and Differentiation

Volumn 22, Issue 12, 2015, Pages 2098-2106

  Goodwin, C M ^a   Rossanese, O W ^a,b   Olejniczak, E T ^a,b   Fesik, S W ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; BIM PROTEIN; MESSENGER RNA; PROTEIN BAK; PROTEIN BCL XL; PROTEIN INHIBITOR; PROTEIN MCL 1; PROTEIN NOXA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VENETOCLAX; WEHI 539; APOPTOSIS REGULATORY PROTEIN; BCL2L11 PROTEIN, HUMAN; FUSED HETEROCYCLIC RINGS; MCL1 PROTEIN, HUMAN; MEMBRANE PROTEIN; ONCOPROTEIN; PMAIP1 PROTEIN, HUMAN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; SULFONAMIDE;

APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER RESISTANCE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CYTOTOXICITY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; TRIPLE NEGATIVE BREAST CANCER; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FEMALE; GENETICS; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BCL-2-LIKE PROTEIN 11; BCL-X PROTEIN; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; MEMBRANE PROTEINS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; RNA, SMALL INTERFERING; SULFONAMIDES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84947492264     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2015.73     Document Type: Article

References (44)

1. Carey LA. Directed therapy of subtypes of triple-negative breast cancer. Oncologist 2011; 16: 71-78.
2. Schmadeka R, Harmon BE, Singh M. Triple-negative breast carcinoma. Am J Clin Pathol 2014; 141: 462-477.
3. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist 2011; 16: 1-11.
4. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434.
5. McCarthy N, Mitchell G, Bilous M, Wilcken N, Lindeman GJ. Triple-negative breast cancer: making the most of a misnomer. Asia Pac J Clin Oncol 2012; 8: 145-155.
6. OToole SA, Beith JM, Millar EKA, West R, McLean A, Cazet A et al. Therapeutic targets in triple negative breast cancer. J Clin Pathol 2013; 66: 530-542.
7. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
8. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014; 15: 49-63.
9. Billard C. BH3 mimetics status of the field and new developments. Mol Cancer Ther 2013; 12: 1691-1700.
10. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011; 29: 909-916.
11. Vogler M, Dinsdale D, Dyer MJS, Cohen GM. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 2009; 16: 360-367.
12. Vaillant F, Merino D, Lee L, Breslin K, Pal B, Ritchie ME et al. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell 2013; 24: 120-129.
13. Goldsmith KC, Lestini BJ, Gross M, Ip L, Bhumbla A, Zhang X et al. BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists. Cell Death Differ 2010; 17: 872-882.
14. Morales AA, Kurtoglu M, Matulis SM, Liu J, Siefker D, Gutman DM et al. Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-x L/Bcl-2 in Mcl-1-expressing myeloma cells. Blood 2011; 118: 1329-1339.
15. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393-403.
16. Thomas LW, Lam C, Edward SW. Mcl-1; the molecular regulation of protein function. FEBS Lett 2010; 584: 2981-2989.
17. Zhang H, Guttikonda S, Roberts L, Uziel T, Semizarov D, Elmore SW et al. Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines. Oncogene 2011; 30: 1963-1968.
18. Zhang Z, Liu Y, Song T, Xue Z, Shen X, Liang F et al. An antiapoptotic Bcl-2 family protein index predicts the response of leukaemic cells to the pan-Bcl-2 inhibitor S1. Br J Cancer. 2013; 108: 1870-1878.
19. Wei G, Margolin AA, Haery L, Brown E, Cucolo L, Julian B et al. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell 2012; 21: 547-562.
20. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463: 899-905.
21. Ding Q, He X, Xia W, Hsu JM, Chen CT, Li LY et al. Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. Cancer Res 2007; 67: 4564-4567.
22. Mitchell C, Yacoub A, Hossein H, Martin AP, Bareford MD, Eulitt P et al. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer Biol Ther 2010; 10: 903-917.
23. Petrocca F, Altschuler G, Tan SM, Mendillo ML, Yan H, Jerry DJ et al. A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells. Cancer Cell 2013; 24: 182-196.
24. Balko JM, Giltname JM, Wang K, Schwarz LJ, Young CD, Cook RS et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov 2014; 4: 232-245.
25. Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011; 471: 110-114.
26. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/ Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389-399.
27. Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res. 2007; 67: 1176-1183.
28. Rooswinkel RW, van de Kooij B, Verheij M, Borst J. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. Cell Death Dis 2012; 3: e366.
29. Zhou P, Levy NB, Xie H, Qian L, Lee CY, Gascoyne RD et al. MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. Blood 2001; 97: 3902-3909.
30. Moulding DA, Giles RV, Spiller DG, White MR, Tidd DM, Edwards SW. Apoptosis is rapidly triggered by antisense depletion of MCL-1 in differentiating U937 cells. Blood 2000; 96: 1756-1763.
31. Chetoui N, Sylla K, Gagnon-Houde JV, Alcaide-Loridan C, Charron D, Al-Daccak R et al. Down-regulation of Mcl-1 by small interfering RNA sensitizes resistant melanoma cells to Fas-mediated apoptosis. Mol Cancer Res 2008; 6: 42-52.
32. Heere-Ress E, Thallinger C, Lucas T, Schlagbauer-Wadl H, Wacheck V, Monia BP et al. Bcl- X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy. Int J Cancer 2002; 99: 29-34.
33. Colak S, Zimberlin CD, Fessler E, Hogdal L, Prasetyanti PR, Grandela CM et al. Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells. Cell Death Differ 2014; 21: 1170-1177.
34. Ryan J, Letai A. BH3 profiling in whole cells by fluorimeter or FACS. Methods 2013; 61: 156-164.
35. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, Letai A. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 351-365.
36. Foight GW, Ryan JA, Gulla SV, Letai A, Keating AE. Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells. ACS Chem Biol. 2014; 9: 1962-1968.
37. Lessene G, Czabotar PE, Sleebs BE, Zobel K, Lowes KN, Adams JM. Structure-guided design of a selective BCL-X(L) inhibitor. Nat Chem Biol 2013; 9: 390-397.
38. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-3428.
39. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202-208.
40. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515-527.
41. Tromp JM, Geest CR, Breij EC, Elias JA, van Laar J, Luijks DM. Tipping the NOXA/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia. Clin Cancer Res 2012; 18: 487-498.
42. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007; 12: 171-185.
43. Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev 2012; 26: 120-125.
44. Al-Harbi S, Hill BT, Mazumder S, Singh K, Devecchio J, Choudhary G. An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood 2011; 118: 3579-3590.